Phase 2 trials showed up to 24% body weight reduction at the highest dose, and Phase 3 data from the TRIUMPH program pushed that number even higher, reaching 28.7% in participants with obesity and knee osteoarthritis
Liraglutide was the first GLP-1 receptor analogue approved for the management of obesity, thus starting the new era of gastrointestinal peptide agonist pharmacotherapy for the treatment of both diabetes and obesity
Customer Service Quality A knowledgeable, responsive support team significantly enhances customer experience
Elevated adiponectin concentrations have been noted in major clinical trials with GLP-1RAs (123, 188) and, more robustly, with tirzepatide (189)
This feedback has led us to explore alternatives to injectable medications on the market
Medication Costs Compounded medications are sourced from licensed US pharmacies like Belmar Pharma Solutions